Renalytix PLC on Tuesday announced a successful fund raise alongside a narrowed annual loss.
The London-based diagnostics company said it had raised £11.8 million via a placing and subscription at 9 pence per share. In a statement on Monday, the firm said it hoped to raise at least £10 million.
Chief Executive James McCullough commented: ‘The strong demand we have seen for the fundraise supports our view that Renalytix offers investors unique access to a world-leading kidney prognostic test.’
He pointed out kidneyintelX.dkd is the only test to be approved by the US Food & Drugs Administration; granted full Medicare reimbursement at $950 per test; recommended in KDIGO clinical guidelines; available to approximately 14 million US diabetic kidney disease patients; and able to address the needs of approximately 260 million DKD patients globally.
‘We now have a strong cash and balance sheet position, we have taken positive actions to substantially reduce our monthly cash burn, and we are delivering quarter-on-quarter growth in orders, whilst also supporting a new customer launch. We believe these factors, combined, will take the company to profitability and cash flow break-even in approximately two years and that we have the potential to generate revenue of approximately $17.5 million in [financial 2027].’
Renalytix said net loss before tax narrowed to $33.5 million in the year ended June 30 from $45.6 million a year prior. Revenue slipped to $2.3 million from $3.4 million but general and administrative costs nosedived to $19.8 million from $28.7 million.
Shares in Renalytix rose 8.1% to 8.64 pence each in London on Tuesday.
Copyright 2024 Alliance News Ltd. All Rights Reserved.
